Geisinger appoints CEO, president

Geisinger, a health system that serves more than 1.5 million patients in Pennsylvania and New Jersey, has named Jaewon Ryu, MD, as its new president and CEO. Ryu, who has served as interim president and CEO since November 2018, will assume the position July 1.

He also previously served as executive vice president and chief medical officer since September 2016. Ryu succeeds David T. Feinberg, MD, MBA, who left Geisinger in late 2018 to take a newly-created role at Google to provide strategic direction for the tech company’s ongoing healthcare businesses. Feinberg had been CEO of the health system since 2015.

“We conducted an exhaustive national search that included some of the brightest, most accomplished health care leaders in the country,” Geisinger Board Chairman John C. Bravman, PhD, said in a statement. “Dr. Ryu has a strong understanding of the Geisinger organization, in addition to broad clinical and management expertise. In his recent roles as chief medical officer and as interim CEO, Dr. Ryu has fostered a culture at Geisinger that pushes us to bring the most innovative care to our patients and communities."

Geisinger’s reach includes 13 hospital campuses, a health plan with nearly 600,000 members, two research centers and the Geisinger Commonwealth School of Medicine.

Before joining Geisinger, Ryu was president of integrated care delivery for Humana and also served as chief medical officer at the University of Illinois Hospitals & Health Services System in Chicago. He has also held roles at Kaiser Permanente, CMS and as a White House Fellow at the Department of Veterans Affairs (VA).

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.